Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 1/2011

01-01-2011 | Materno-fetal Medicine

Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration

Author: Ioannis Mylonas

Published in: Archives of Gynecology and Obstetrics | Issue 1/2011

Login to get access

Abstract

Background

Infections during gestation, delivery and the postnatal period can jeopardise not only the mother, but also the child. Along with chromosomal abnormalities and immunological diseases, infection in early pregnancy represents the most important reason for abortion. During the second and third trimester, infections are the principal cause for preterm labour, premature membrane rupture, premature delivery and the resultant complications in the newborn child. Many pregnant women are very cautious about taking antibiotics due to primarily potentially detrimental effects on the unborn child. However, there are no contraindications for antibiotic treatment during pregnancy in the event of a serious infectious disease of the mother.

Materials and methods

In this review the indications and contraindications of the administration of antibiotics during pregnancy are being reviewed.

Results

Penicillins are a first-line antibiotic treatment during pregnancy, with the exception of cases in which there is a maternal allergy to penicillin. Cephalosporins are another first-line antibiotic used during pregnancy. In principle, more commonly used cephalosporins should be given priority. Owing to associated nephrotoxicity and ototoxicity, aminoglycosides should not be prescribed at any time during pregnancy. Systematic use of aminoglycosides should be considered solely in the event of life-threatening infections with gram-negative pathogens and/or treatment failure of recommended antibiotics during pregnancy. The use of metronidazole is also permitted during pregnancy, provided the indications for its use have been strictly verified. Lincosamides should be used only if penicillins, cephalosporins and erythromycin have failed to eradicate infection. Sulfonamides, trimethoprim and cotrimoxazole are second-line agents for the use during pregnancy. Tetracyclines should not be administered to pregnant women after the fifth week of pregnancy, and are deemed contraindicated. As a precautionary measure, gyrase inhibitors are also contraindicated for pregnant women, children and young adolescents.

Conclusion

On the basis of our current state of knowledge, the vast majority of antibiotics do not cause serious harm to the unborn child if used properly and at the appropriate doses during pregnancy. The treatment with an antibiotic that is contraindicated does not justify termination of pregnancy. However, ultimately no medicine, including antibiotics, can be described as absolutely safe.
Literature
1.
go back to reference Mylonas I, Dian D, Friese K (2005) Antibiotikatherapie in der Schwangerschaft. Gynakologe 38:761–770CrossRef Mylonas I, Dian D, Friese K (2005) Antibiotikatherapie in der Schwangerschaft. Gynakologe 38:761–770CrossRef
2.
go back to reference Mylonas I, Friese K (2009) Infektionen in der Gynäkologien und Geburtshilfe. Elsevier Verlag/Urban & Fischer, München Mylonas I, Friese K (2009) Infektionen in der Gynäkologien und Geburtshilfe. Elsevier Verlag/Urban & Fischer, München
3.
go back to reference Friese K, Schäfer A, Hof H (2002) Infektionen in der Gynäkologie und Geburtshilfe. Springer, Berlin Friese K, Schäfer A, Hof H (2002) Infektionen in der Gynäkologie und Geburtshilfe. Springer, Berlin
4.
go back to reference Friese K, Mörike K, Neumann G, Windorfer A (2009) Arzneimittel in der Schwangerschaft und Stillzeit: Ein Leitfaden für Ärzte und Apotheker Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart Friese K, Mörike K, Neumann G, Windorfer A (2009) Arzneimittel in der Schwangerschaft und Stillzeit: Ein Leitfaden für Ärzte und Apotheker Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart
5.
go back to reference Friese K, Melchert F (2002) Arzneimitteltherapie in der Frauenheilkunde. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart Friese K, Melchert F (2002) Arzneimitteltherapie in der Frauenheilkunde. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart
6.
go back to reference Briggs GG, Freeman RK, Yaffe SJ (1998) Drugs in pregnancy and lactation. Williams & Wilkins, Baltimore Briggs GG, Freeman RK, Yaffe SJ (1998) Drugs in pregnancy and lactation. Williams & Wilkins, Baltimore
7.
go back to reference Saunders EJ, Saunders JA (1990) Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int 11:423–432CrossRefPubMed Saunders EJ, Saunders JA (1990) Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int 11:423–432CrossRefPubMed
8.
go back to reference (2001) Erythromycin-induced pyloric stenosis in infants. Prescrire Int 10:16 (2001) Erythromycin-induced pyloric stenosis in infants. Prescrire Int 10:16
9.
go back to reference Mahon BE, Rosenman MB, Kleiman MB (2001) Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 139:380–384CrossRefPubMed Mahon BE, Rosenman MB, Kleiman MB (2001) Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 139:380–384CrossRefPubMed
10.
go back to reference Norgaard M, Skriver MV, Sorensen HT, Schonheyder HC, Pedersen L (2008) Risk of miscarriage for pregnant users of pivmecillinam: a population-based case–control study. APMIS 116:278–283PubMed Norgaard M, Skriver MV, Sorensen HT, Schonheyder HC, Pedersen L (2008) Risk of miscarriage for pregnant users of pivmecillinam: a population-based case–control study. APMIS 116:278–283PubMed
11.
go back to reference Sa del Fiol F, Gerenutti M, Groppo FC (2005) Antibiotics and pregnancy. Pharmazie 60:483–493PubMed Sa del Fiol F, Gerenutti M, Groppo FC (2005) Antibiotics and pregnancy. Pharmazie 60:483–493PubMed
12.
go back to reference Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J (2006) Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 15:327–337CrossRefPubMed Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J (2006) Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population. Pharmacoepidemiol Drug Saf 15:327–337CrossRefPubMed
13.
go back to reference Bertsche T, Haas M, Oberwittler H, Haefeli WE, Walter-Sack I (2006) Drugs during pregnancy and breastfeeding: new risk categories—antibiotics as a model. Dtsch Med Wochenschr 131:1016–1022CrossRefPubMed Bertsche T, Haas M, Oberwittler H, Haefeli WE, Walter-Sack I (2006) Drugs during pregnancy and breastfeeding: new risk categories—antibiotics as a model. Dtsch Med Wochenschr 131:1016–1022CrossRefPubMed
14.
go back to reference Nahum GG, Uhl K, Kennedy DL (2006) Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 107:1120–1138CrossRefPubMed Nahum GG, Uhl K, Kennedy DL (2006) Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol 107:1120–1138CrossRefPubMed
15.
16.
go back to reference Schäfer C, Spielman H (2001) Arzneimittelverordnung in Schwangerschaft und Stillzeit. Elsevier Urban und Fischer, Berlin, Jena Schäfer C, Spielman H (2001) Arzneimittelverordnung in Schwangerschaft und Stillzeit. Elsevier Urban und Fischer, Berlin, Jena
17.
go back to reference Dencker BB, Larsen H, Jensen ES, Schonheyder HC, Nielsen GL, Sorensen HT (2002) Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 8:196–201CrossRefPubMed Dencker BB, Larsen H, Jensen ES, Schonheyder HC, Nielsen GL, Sorensen HT (2002) Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 8:196–201CrossRefPubMed
18.
go back to reference Lewis DF, Adair CD, Robichaux AG, Jaekle RK, Moore JA, Evans AT, Fontenot MT (2003) Antibiotic therapy in preterm premature rupture of membranes: are seven days necessary? A preliminary, randomized clinical trial. Am J Obstet Gynecol 188:1413–1416 (discussion 1416–1417)CrossRefPubMed Lewis DF, Adair CD, Robichaux AG, Jaekle RK, Moore JA, Evans AT, Fontenot MT (2003) Antibiotic therapy in preterm premature rupture of membranes: are seven days necessary? A preliminary, randomized clinical trial. Am J Obstet Gynecol 188:1413–1416 (discussion 1416–1417)CrossRefPubMed
19.
go back to reference Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case–control teratologic study. Eur J Obstet Gynecol Reprod Biol 97:188–192CrossRefPubMed Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case–control teratologic study. Eur J Obstet Gynecol Reprod Biol 97:188–192CrossRefPubMed
20.
go back to reference Sigg TR, Kuhn BR (2000) Inadvertent intrauterine infusion of ampicillin–sulbactam. Am J Health Syst Pharm 57:215PubMed Sigg TR, Kuhn BR (2000) Inadvertent intrauterine infusion of ampicillin–sulbactam. Am J Health Syst Pharm 57:215PubMed
21.
go back to reference Simon C, Stille W (2000) Antibiotika—Therapie in Klinik und Praxis. Schattauer, Stuttgart Simon C, Stille W (2000) Antibiotika—Therapie in Klinik und Praxis. Schattauer, Stuttgart
22.
go back to reference Garratty G, Leger RM, Arndt PA (1999) Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol 181:103–104CrossRefPubMed Garratty G, Leger RM, Arndt PA (1999) Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol 181:103–104CrossRefPubMed
23.
go back to reference Berkovitch M, Segal-Socher I, Greenberg R, Bulkowshtein M, Arnon J, Merlob P, Or-Noy A (2000) First trimester exposure to cefuroxime: a prospective cohort study. Br J Clin Pharmacol 50:161–165CrossRefPubMed Berkovitch M, Segal-Socher I, Greenberg R, Bulkowshtein M, Arnon J, Merlob P, Or-Noy A (2000) First trimester exposure to cefuroxime: a prospective cohort study. Br J Clin Pharmacol 50:161–165CrossRefPubMed
24.
go back to reference Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case–control study. Am J Obstet Gynecol 184:1289–1296CrossRefPubMed Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (2001) Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case–control study. Am J Obstet Gynecol 184:1289–1296CrossRefPubMed
25.
go back to reference Manka W, Solowiow R, Okrzeja D (2000) Assessment of infant development during an 18-month follow-up after treatment of infections in pregnant women with cefuroxime axetil. Drug Saf 22:83–88CrossRefPubMed Manka W, Solowiow R, Okrzeja D (2000) Assessment of infant development during an 18-month follow-up after treatment of infections in pregnant women with cefuroxime axetil. Drug Saf 22:83–88CrossRefPubMed
26.
go back to reference Heikkila A, Erkkola R (1994) Review of β-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 27:49–62CrossRefPubMed Heikkila A, Erkkola R (1994) Review of β-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 27:49–62CrossRefPubMed
27.
go back to reference Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (1999) A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13:531–536CrossRefPubMed Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J (1999) A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13:531–536CrossRefPubMed
28.
go back to reference Einarson A, Phillips E, Mawji F, D’Alimonte D, Schick B, Addis A, Mastroiacova P, Mazzone T, Matsui D, Koren G (1998) A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523–525CrossRefPubMed Einarson A, Phillips E, Mawji F, D’Alimonte D, Schick B, Addis A, Mastroiacova P, Mazzone T, Matsui D, Koren G (1998) A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523–525CrossRefPubMed
29.
go back to reference Schick B, Hom M, Librizzi R, Donnenfeld A (1996) Pregnancy outcome following exposure to clarithromycin. Reprod Toxicol 10:162 Schick B, Hom M, Librizzi R, Donnenfeld A (1996) Pregnancy outcome following exposure to clarithromycin. Reprod Toxicol 10:162
30.
go back to reference Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A case–control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 79:234–237CrossRefPubMed Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A case–control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 79:234–237CrossRefPubMed
31.
go back to reference Kallen BA, Otterblad Olausson P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20:209–214PubMed Kallen BA, Otterblad Olausson P, Danielsson BR (2005) Is erythromycin therapy teratogenic in humans? Reprod Toxicol 20:209–214PubMed
32.
go back to reference Schardein JL (2000) Chemically induced birth defects. Marcel Dekker, New York Schardein JL (2000) Chemically induced birth defects. Marcel Dekker, New York
33.
go back to reference Lewis JH (1991) Drug hepatotoxicity in pregnancy. Eur J Gastroenterol Hepatol 3:883–891 Lewis JH (1991) Drug hepatotoxicity in pregnancy. Eur J Gastroenterol Hepatol 3:883–891
34.
go back to reference Trexler MF, Fraser TG, Jones MP (1997) Fulminant pseudomembranous colitis caused clindamycin phosphate vaginal cream. Am J Gastroenterol 92:2113 Trexler MF, Fraser TG, Jones MP (1997) Fulminant pseudomembranous colitis caused clindamycin phosphate vaginal cream. Am J Gastroenterol 92:2113
35.
go back to reference Joesoef M, Schmid G (2002) Bacterial vaginosis. Clin Evid 1592–1600 Joesoef M, Schmid G (2002) Bacterial vaginosis. Clin Evid 1592–1600
36.
go back to reference Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 32:309–313CrossRefPubMed Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT (2000) A teratological study of aminoglycoside antibiotic treatment during pregnancy. Scand J Infect Dis 32:309–313CrossRefPubMed
37.
go back to reference Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole: a therapeutic review and update. Drugs 54:679–708CrossRefPubMed Freeman CD, Klutman NE, Lamp KC (1997) Metronidazole: a therapeutic review and update. Drugs 54:679–708CrossRefPubMed
38.
go back to reference Diav-Citrin O, Gotteiner T, Shechtman S, Arnon J, Ornoy A (2000) Pregnancy outcome following gestational exposure to metronidazole: a prospective controlled cohort study (abstract). Teratology 61:440 Diav-Citrin O, Gotteiner T, Shechtman S, Arnon J, Ornoy A (2000) Pregnancy outcome following gestational exposure to metronidazole: a prospective controlled cohort study (abstract). Teratology 61:440
39.
go back to reference Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF, Roberson P, Pais R, Ray WA (1998) Prenatal exposure to metronidazole and risk of childhood cancer. Cancer 83:1461–1468CrossRefPubMed Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF, Roberson P, Pais R, Ray WA (1998) Prenatal exposure to metronidazole and risk of childhood cancer. Cancer 83:1461–1468CrossRefPubMed
40.
go back to reference Beard CM, Noller KL, O’Fallon WM, Kurland LT, Dahlin DC (1988) Cancer after exposure to metronidazole. Mayo Clin Proc 63:147–153PubMed Beard CM, Noller KL, O’Fallon WM, Kurland LT, Dahlin DC (1988) Cancer after exposure to metronidazole. Mayo Clin Proc 63:147–153PubMed
41.
go back to reference Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvares-Requejo A, Rodriguez-Pinilla E (1997) Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179–182CrossRefPubMed Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Alvares-Requejo A, Rodriguez-Pinilla E (1997) Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 44:179–182CrossRefPubMed
42.
go back to reference Czeizel AE, Rockenbauer M (1998) A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 105:2–7 Czeizel AE, Rockenbauer M (1998) A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 105:2–7
43.
go back to reference Czeizel AE (1990) A case–control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 4:305–313CrossRefPubMed Czeizel AE (1990) A case–control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 4:305–313CrossRefPubMed
44.
go back to reference Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, Littleton Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, Littleton
45.
go back to reference Friese K, Hlobil H (1997) Prenatal toxoplasmosis: is screening in pregnancy necessary? Z Geburtshilfe Neonatol 201:115–120PubMed Friese K, Hlobil H (1997) Prenatal toxoplasmosis: is screening in pregnancy necessary? Z Geburtshilfe Neonatol 201:115–120PubMed
46.
go back to reference Friese K (1994) Diagnosis and treatment of congenital toxoplasmosis. Geburtshilfe Und Frauenheilkunde 54:M99–M101PubMed Friese K (1994) Diagnosis and treatment of congenital toxoplasmosis. Geburtshilfe Und Frauenheilkunde 54:M99–M101PubMed
47.
go back to reference Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF (1981) Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 26:135–141PubMed Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF (1981) Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med 26:135–141PubMed
48.
go back to reference Whalley PJ, Martin FG, Adams RH, Combes B (1970) Disposition of tetracycline by pregnant women with acute pyelonephritis. Obstet Gynecol 36:821–826PubMed Whalley PJ, Martin FG, Adams RH, Combes B (1970) Disposition of tetracycline by pregnant women with acute pyelonephritis. Obstet Gynecol 36:821–826PubMed
49.
go back to reference Czeizel AE, Rockenbauer M (2000) A population-based case–control study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 88:27–33CrossRefPubMed Czeizel AE, Rockenbauer M (2000) A population-based case–control study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 88:27–33CrossRefPubMed
50.
go back to reference Takayama S, Watanabe T, Akiyama Y, Ohura K, Harada S, Matsuhashi K, Mochida K, Yamashita N (1986) Reproductive toxicity of ofloxacin. Arzneimittelforschung 36:1244–1248PubMed Takayama S, Watanabe T, Akiyama Y, Ohura K, Harada S, Matsuhashi K, Mochida K, Yamashita N (1986) Reproductive toxicity of ofloxacin. Arzneimittelforschung 36:1244–1248PubMed
51.
go back to reference Gough AW, Kasali OB, Sigler RE, Baragi V (1992) Quinolone arthropathy acute toxicity to immature articular cartilage. Toxicol Pathol 20:436–449CrossRefPubMed Gough AW, Kasali OB, Sigler RE, Baragi V (1992) Quinolone arthropathy acute toxicity to immature articular cartilage. Toxicol Pathol 20:436–449CrossRefPubMed
52.
go back to reference Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexieder T, Prapas N, Merlob P (1996) Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 69:83–89CrossRefPubMed Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexieder T, Prapas N, Merlob P (1996) Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol 69:83–89CrossRefPubMed
53.
go back to reference Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G (1994) Safety of the new quinolones in pregnancy. Obstet Gynecol 84:535–538PubMed Berkovitch M, Pastuszak A, Gazarian M, Lewis M, Koren G (1994) Safety of the new quinolones in pregnancy. Obstet Gynecol 84:535–538PubMed
54.
go back to reference Loebstein R, Addis A, Ho E, Andreou R et al (1998) Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 42:1336–1339PubMed Loebstein R, Addis A, Ho E, Andreou R et al (1998) Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 42:1336–1339PubMed
Metadata
Title
Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration
Author
Ioannis Mylonas
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 1/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1646-3

Other articles of this Issue 1/2011

Archives of Gynecology and Obstetrics 1/2011 Go to the issue

Acknowledgement to Referees

Reviewers 2010